CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma

Cancer Research

Volumn 56, Issue 23, 1996, Pages 5443-5449

  Mazzoni, Alessandra ^a   Mezzanzanica, Delia ^a   Jung, Gundram ^b   Wolf, Hans ^b,c   Colnaghi, Maria I ^a   Canevari, Silvana ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MUNICH   (Germany)

^c Baxter GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; FOLATE BINDING PROTEIN; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; APOPTOSIS; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; EFFECTOR CELL; HUMAN; HUMAN CELL; MINIMAL RESIDUAL DISEASE; MONONUCLEAR CELL; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, CD28; ANTIGENS, CD3; CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; COCULTURE TECHNIQUES; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; LYMPHOKINES; NEOPLASM PROTEINS; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; RECEPTOR-CD3 COMPLEX, ANTIGEN, T-CELL; RECEPTORS, CELL SURFACE; T-LYMPHOCYTE SUBSETS; TUMOR CELLS, CULTURED;

EID: 0030466658     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Renner, C., and Pfreundschuh, M. Tumor therapy by immune recruitment with bispecific antibodies. Immunol. Rev., 145: 179-209, 1995.
2. + killing of tumor target cells coated with anti-target-anti-T3 conjugates Proc. Natl. Acad. Sci. USA, 83. 4479-4483, 1986
3. Pupa, S M, Canevari, S., Fontanelli, R., Ménard, S., Mezzanzanica, D , Lanzavecchia, A., and Colnaghi, M. I. Activation of mononuclear cells to be used for hybrid monoclonal antibody-induced lysis of human ovarian carcinoma cells. Int. J. Cancer, 42: 455-459, 1988.
4. Garrido, M A., Perez, P , Titus, J A., Valdayo, M J., Winkler, D. F , Barbieri, S. A., Wunderlich, J R., and Segal, D. M Targeted cytotoxic cells in human peripheral blood lymphocytes J Immunol., 144: 2891-2898, 1990.
5. Mueller, D. L., Jenkins, M K , and Schwartz, R H. Clonal expansion vs functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu. Rev. Immunol., 7: 445-480, 1989
6. Oshimi, K., Seto, T., Oshimi, Y., Masuda, M , Okumura, K., and Mizoguchi, H. Increased lysis of panent CD10-positive leukemic cells by T cells coated with anti-CD3 Fab′ antibody cross-linked to anti-CD10 Fab′ antibody. Blood, 77: 1044-1049, 1991.
7. Reid, I., Lundy, J., and Donohue, J. H. Enhancement of in vitra tumor-infiltrating lymphocyte cytotoxicity by heteroconjugated antibodies. J. Immunol., 148: 2630-2635, 1992.
8. Bernhard, H., Karbach, J., Strittmatter, W., Meyer Zum Buschenfelde, K-H., and Knuth. A Induction of rumor-cell lysis by bi-specific antibody recognizing ganglioside GD2 and T-cell antigen CD3. Int. J. Cancer, 55. 465-470, 1993.
9. Beun, G. D. M., Gorter, A., Nooyen, Y., Van de Velde, C. J. H., and Fleuren, G J T cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model. J. Immunol., 150: 2305-2315, 1993.
10. Haagen, I-A., Geerars, A J., de Lau, W B , Clark, M. R., Van de Griend, R. J., Bast, B J., and De Gast, B. C. Killing of autologous B-lineage malignancy using CD3 X CD19 bispecific monoclonal antibody in end stase leukemia and lymphoma Blood, 84: 556-563, 1994.
11. 1 lymphoma. Cancer Res , 54: 2973-2978, 1994.
12. Belen Moreno, M , Titus, J. A., Cole, M. S., Yun Tso, J , Le, N., Paik, C H., Bakacs, T., Zacharchuk, C M, Segal, D M., and Wunderlich, J. R Bispecific antibodies retarget murine T cell cytotoxicity against syngeneic breast cancer in vitro and in vivo Cancer Immunol. Immunother., 40: 182-190, 1995.
13. Nitta, T., Sato, K., Yagita, H. Okumura, K., and Ishii, S. Preliminary trial of specific targeting therapy against malignant glioma. Lancet, 335 368-371, 1990.
14. Canevari, S., Stoter, G., Arienti, F., Bolis, G , Colnaghi, M. I., Di Re, E , Eggermont, A. M. M., Goey, S H., Gratama, J. W., Lamers, C H. J., Nooy, M A., Parmiani, G., Raspagliesi, F , Ravagnani, P., Scarfone, G., Trimbos, J. B., Warnaar, S. O , and Bolhuis, R. L. H. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T-lymphocytes retargeted by a bispecific monoclonal antibody. J. Natl. Cancer Inst , 87: 1463-1469, 1995
15. Schwartz, R H. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell, 71: 1065-1068, 1992.
16. Janeway, C A., Jr., and Bottomly, K. Signals and signs for lymphocyte responses. Cell, 76, 275-285, 1994.
17. Jung, G., Ledbetter, J. A., and Müller-Eberhard, H. J. Induction of cytocoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates. Proc. Natl. Acad. Sci USA, 84. 4611-4615, 1987
18. Jung, G , and Muller-Eberhard, H. J. An in vitro model for immunotherapy with antibody heteroconjugares. Immunol Today, 9. 257-260, 1988
19. Bohlen, H., Manzke, O., Patel, B., Moldenhauer, G., Dörken, B., von Fliedner, V., Diehl, V., and Tesch, H. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies. Cancer Res., 53. 4310-4314, 1993.
20. Pohl, C., Denfeld, R., Renner, C., Jung, W., Bohlen, H., Sahin, U , Hombach, A., van Lier, R., Schwonzen, M , Diehl, V , and Pfreundschuh, M CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma. Int. J. Cancer, 54: 820-827, 1993.
21. Blum, S., Milesi, R., Tratkiewicz, J., Olive, D., Gallati, H , Cerottini, J-C , and von Fliedner, V. Rapid induction of cytolytic T cells via CD28 stimulation for cellular immunotherapy Ther. Immunol., 1: 143-152, 1994.
22. Bohlen, H., Hopff, T., Manzke, O., Engert, A., Kube, D , Wickramanayake, P. D., Diehl, V , and Tesch, H. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 × CD19 bispecific antibodies in combination with bivalent CD28 antibodies Blood, 82: 1803-1812, 1993.
23. Renner, C , Jung, W., Sahin, U., van Lier, R , and Pfreundschuh, M. The role of lymphocyte subsets and adhesion molecules in T cell-dependent cytotoxicity mediated by CD3 and CD28 bispecific monoclonal antibodies. Eur. J. Immunol., 25, 2027-2033, 1995.
24. Kroesen, B. J., Bakker, A., Van Lier, R. A. W., The, H. T., and de Leij, L. Bispecific antibody-mediated target cell-specific costimulation of resting T cells via CD5 and CD28. Cancer Res., 55: 4409-4415, 1995
25. Renner, C., Jung, W., Sahin, U., Denfeld, R., Pohl, C., Trümper, L., Hartmann, F., Diehl, V., van Lier, R., and Pfreundschuh, M. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science (Washington DC), 264. 833-835, 1994.
26. Miotti, S., Canevari, S., Ménard, S., Mezzanzanica, D., Porro, G., Pupa, S. M., Regazzoni, M., Tagliabue, E., and Colnaghi, M. I. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity Int. J. Cancer, 39: 297-303, 1987.
27. Coney, L. R., Tomassetti, A., Carayannopoulos, L., Frasca, V., Kamen, B. A., Colnaghi, M. I., and Zurawski, V. R. Cloning of a tumor-associated antigen MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res., 51, 6125-6132, 1991.
28. Lanzavecchia, A., and Scheidegger, D. The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur. J. Immunol., 17: 105-111, 1987
29. Mezzanzanica, D , Canevari, S., Ménard, S., Pupa, S. M., Tagliabue, E., Lanzavecchia, A., and Colnaghi, M. I. Human ovarian carcinoma lysis by cytotoxicity T cells targeted by bispecific monoclonal antibodies: analysis of the antibody components. Int J. Cancer. 41: 609-615, 1988.
30. 2 antibody prolong host survival in a murine xenograft model Cancer Res , 51: 5716-5721, 1991.
31. Mezzanzanica, D., Canevari, S , and Colnaghi, M. I. Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: from laboratory to clinic. Int. J. Clin. Lab. Res., 21, 159-164, 1991.
32. Jung, G., Freimann, U , Von Marschall, Z , Reisfeld, R A., and Wilmanns, W. Target cell-induced T cell activation with bi- and trispecific antibody fragments. Eur. J Immunol , 21 2431-2435, 1991.
33. Mosmann, T. Rapid colorimetric assay for cellular growth and survival application to proliferation and cytotoxicity assays J Immunol. Methods. 65: 55-63, 1983
34. Ferrini, S., Cambiaggi, A., Sforzini, S , Marciano, S., Canevari, S., Mezzanzanica, D., Colnaghi, M I., Grossi, C. E., and Moretta, L Targeting of T lymphocytes against EGF-receptor + tumor cells by bispecific monoclonal antibodies, requirement of CD3 molecule cross-linking for T-cell activation. Int. J. Cancer, 55: 931-937, 1993.
35. Qian, J-H., Titus, J. A., Andrew, S. M., Mezzanzanica, D., Garrido, M. A., Wunderlich, J R , and Segal, D. M. Human peripheral blood lymphocytes targeted with bispecific antibodies release cytokines that are essential for inhibiting tumor growth. J. Immunol , 146: 3250-3256, 1991.
36. Segal, D. M., Qian, J., Titus, J. A., Moreno, M B., George, A. J. T., Josi, C. R., Kurucz, I , El-Gamil, M., and Wunderlich, J. R. Targeted cytokine production Int J. Cancer, 52 (Suppl. 7): 36-38, 1992.
37. Lindsten, T , June, C H., Ledbetter, J A , Stella, G., and Thompson, C. B. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science (Washington DCX 244: 339-343, 1989
38. Thompson, C. B., Lindsten, T , Ledbetter, J. A , Kunkel, S L., Young, H A , Emerson, S. G., Leiden, J. M., and June, C H CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc. Natl. Acad. Sci. USA, 86: 1333-1337, 1989.
39. Risso, A., Smilovich, D., Capra, M. C., Baldissarro, I., Yan, G., Bargellesi, A , and Cosulich, M. E CD69 in resting and activated T lymphocytes. J. Immunol., 146: 4105-4114, 1991.
40. Vandenberghe, P , Verwilghen, J., Van Vaeck, F., and Ceuppens, J. L. Ligation of the CD5 or CD28 molecules on resting human T cells induces expression of the early activation antigen CD69 by a calcium- and tyrosine kinase-dependent mechanism. Immunology, 78. 210-217, 1993.
41. Taniguchi, T , and Minami, Y The IL-2/IL-2 receptor system a current overview. Cell, 73: 5-8, 1993.
42. Liu, Y , and Janeway, C. A , Jr. Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T cells Proc Natl Acad Sci. USA, 89: 3845-3849, 1992.
43. Levine, B. L., Ueda, Y., Craighead, N , Huang, M. L., and June, C H. CD28 ligands CD80 (B7-1) and CD86 (B7-2) induce long-term autocrine growth of CD4+ T cells and induce similar patterns of cytokine secretion in vitro Int. Immunol., 7: 891-904, 1995.
44. Azuma, M , Cayabyab, M., Phillips, J. H., and Lanier, L. L. Requirements for CD28-dependent T cell-mediated cytotoxicity. J. Immunol., 150: 2091-2101, 1993.
45. Blank-Voorthuis, C J A C, Braakman, E , Ronteltap, C. P M , Tilly, B. C., Sturm, E., Warnaar, S. O., and Bolhuis, R. L H Clustered CD3/TCR complexes do not transduce activation signals after bispecific monoclonal antibody-triggered lysis by cytotoxic T lymphocytes via CD3. J. Immunol. 151: 2904-2914, 1993